Christin Melton, ELS, CMPP

A research team led by investigators at the University of Texas Southwestern Medical Center in Dallas has published a study in Nature Communications identifying several new genetic mutations in pancreatic ductal adenocarcinoma.

Immunotherapy vaccine approaches that involve harvesting a patient’s dendritic cells and priming them to recognize a tumor-specific antigen before injecting them back into the patient to activate a T-cell response against the tumor have achieved encouraging but limited success.

Growth in healthcare spending in the United States continues to outpace growth in European countries that enjoy a similar standard of living.

Harold Varmus, MD, may be stepping down as director of the National Cancer Institute (NCI) at the end of March, but in an interview with Targeted Oncology, he made it clear that he is not retiring.

Many patients with non–small cell lung cancer (NSCLC) have no identifiable mutations, and therefore their disease cannot be managed with targeted treatments.

Novartis Oncology hopes to overcome many of these challenges with the innovative Signature Clinical Trial program, which “bring[s] the ‘Protocol to the Patient.

An international team of scientists has shed additional light on the important role of Yes-associated protein (YAP) in tumor development and in treatment response.

Targeted agents have become available in recent years to treat many major cancers, but for women with ovarian cancer, standard treatment following cytoreductive surgery remains systemic intravenous/intraperitoneal chemotherapy with a platinum agent and a taxane. Approximately 80% of women who receive first-line treatment with this platinum-based regimen experience relapsed disease. However, early research indicates that more and better options may be on the way.

With appropriate treatment, individuals with thyroid cancer have good odds for survival—the 5-year survival rate is 98%. Many factors influence the risk of survival after thyroid cancer is diagnosed.

Every time you check out at the supermarket with your customer loyalty card, a computer makes a record of your purchases, which links to your demographic profile.

Researchers for Caris Life Sciences have used the company's proprietary tumor profiling platform to identify biomarkers in GIST that may be used to identify more effective therapeutic regimens for individuals with TKI-resistant GIST.

The New York State Stem Cell Science Program recently awarded a 4-year $11.9 million grant to Roswell Park Cancer Institute to fund research and development of a stem-cell based treatment for ovarian cancer.